{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:44:46Z","timestamp":1768250686656,"version":"3.49.0"},"reference-count":66,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Applying the principles of evidence-based medicine to febrile neutropenia (FN) results in a more limited set of practices than expected. Hundreds of studies over the last 4 decades have produced evidence to support the following: (1) risk stratification allows the identification of a subset of patients who may be safely managed as outpatients given the right health care environment; (2) antibacterial prophylaxis for high-risk patients who remain neutropenic for \u2265 7 days prevents infections and decreases mortality; (3) the empirical management of febrile neutropenia with a single antipseudomonal beta-lactam results in the same outcome and less toxicity than combination therapy using aminoglycosides; (4) vancomycin should not be used routinely empirically either as part of the initial regimen or for persistent fever, but rather should be added when a pathogen that requires its use is isolated; (5) empirical antifungal therapy should be added after 4 days of persistent fever in patients at high risk for invasive fungal infection (IFI); the details of the characterization as high risk and the choice of agent remain debatable; and (6) preemptive antifungal therapy in which the initiation of antifungals is postponed and triggered by the presence, in addition to fever, of other clinical findings, computed tomography (CT) results, and serological tests for fungal infection is an acceptable strategy in a subset of patients. Many practical management questions remain unaddressed.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.414","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"414-422","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies"],"prefix":"10.1182","volume":"2013","author":[{"given":"Juan","family":"Gea-Banacloche","sequence":"first","affiliation":[{"name":"Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"7023","key":"2019111705320853200_B1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: what it is and what it isn't","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"2019111705320853200_B2","unstructured":"Group\n              OLOEW\n            \n          \n          The Oxford 2011 levels of evidence. Oxford centre for evidence-based medicine\n          Accessed August 26, 2013\n          \n            http:\/\/www.cebm.net\/mod_product\/design\/files\/CEBM-Levels-of-Evidence-2.1.pdf"},{"key":"2019111705320853200_B3","unstructured":"Howick\n              J\n            \n            \n              Chalmers\n              I\n            \n            \n              Glasziou\n              P\n            \n            \n              Greenhalgh\n              T\n            \n            \n              Heneghan\n              C\n            \n            \n          \n          The 2011 Oxford CEBM levels of evidence: Introductory document\n          Accessed August 26, 2013\n          \n            http:\/\/www.cebm.net\/index.aspx?o=5653"},{"issue":"3","key":"2019111705320853200_B4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1086\/598620","article-title":"Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria","volume":"29","author":"Zinner","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2019111705320853200_B5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/JCM.44.1.160-165.2006","article-title":"Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases","volume":"44","author":"Han","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"2","key":"2019111705320853200_B6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1086\/514550","article-title":"Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials","volume":"25","author":"Elting","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2019111705320853200_B7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-108-1-30","article-title":"Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia","volume":"108","author":"Rubin","year":"1988","journal-title":"Ann Intern Med"},{"issue":"2","key":"2019111705320853200_B8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0002-9343(86)90257-3","article-title":"Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia","volume":"81","author":"Karp","year":"1986","journal-title":"Am J Med"},{"issue":"3","key":"2019111705320853200_B9","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1086\/376637","article-title":"Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy","volume":"37","author":"Cometta","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2019111705320853200_B10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/jac\/dki028","article-title":"Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Paul","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2019111705320853200_B11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1473-3099(05)70164-X","article-title":"Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials","volume":"5","author":"Vardakas","year":"2005","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2019111705320853200_B12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/infdis\/161.3.381","article-title":"From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever","volume":"161","author":"Hughes","year":"1990","journal-title":"J Infect Dis"},{"issue":"4","key":"2019111705320853200_B13","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019111705320853200_B14","doi-asserted-by":"crossref","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","article-title":"Management of febrile neutropenia: ESMO Clinical Practice Guidelines","volume":"21","author":"de Naurois","year":"2010","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111705320853200_B15","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2019111705320853200_B16","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.6004\/jnccn.2012.0146","article-title":"Prevention and treatment of cancer-related infections","volume":"10","author":"Baden","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2019111705320853200_B17","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","article-title":"Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"31","author":"Flowers","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111705320853200_B18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/annonc\/mdp163","article-title":"Management of febrile neutropenia: ESMO clinical recommendations","volume":"20","author":"Marti","year":"2009","journal-title":"Ann Oncol"},{"issue":"1b","key":"2019111705320853200_B19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1445-5994.2010.02338.x","article-title":"Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010\/2011. Australian Consensus Guidelines 2011 Steering Committee","volume":"41","author":"Lingaratnam","year":"2011","journal-title":"Intern Med J"},{"issue":"35","key":"2019111705320853200_B20","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1200\/JCO.2012.42.7161","article-title":"Guideline for the management of fever and neutropenia in children with cancer and\/or undergoing hematopoietic stem-cell transplantation","volume":"30","author":"Lehrnbecher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7652","key":"2019111705320853200_B21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7651","key":"2019111705320853200_B22","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"1b","key":"2019111705320853200_B23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1445-5994.2010.02341.x","article-title":"Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee","volume":"41","author":"Slavin","year":"2011","journal-title":"Intern Med J"},{"issue":"3","key":"2019111705320853200_B24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.seminhematol.2009.03.002","article-title":"Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes","volume":"46","author":"Bow","year":"2009","journal-title":"Semin Hematol"},{"issue":"4","key":"2019111705320853200_B25","first-page":"356","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"6b","key":"2019111705320853200_B26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1445-5994.2008.01723.x","article-title":"Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy","volume":"38","author":"Slavin","year":"2008","journal-title":"Int Med J"},{"issue":"10","key":"2019111705320853200_B27","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ejca.2005.03.006","article-title":"Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials","volume":"41","author":"van de Wetering","year":"2005","journal-title":"Eur J Cancer"},{"issue":"12 Pt 1","key":"2019111705320853200_B28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","article-title":"Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients","volume":"142","author":"Gafter-Gvili","year":"2005","journal-title":"Ann Intern Med"},{"key":"2019111705320853200_B29","first-page":"CD004386","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"34","key":"2019111705320853200_B30","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","article-title":"Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis","volume":"25","author":"Robenshtok","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111705320853200_B31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111705320853200_B32","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111705320853200_B33","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2013a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"issue":"10","key":"2019111705320853200_B34","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2019111705320853200_B35","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-138-9-200305060-00006","article-title":"Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial","volume":"138","author":"Winston","year":"2003","journal-title":"Ann Intern Med"},{"issue":"4","key":"2019111705320853200_B36","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2019111705320853200_B37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111705320853200_B38","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111705320853200_B39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00520-013-1758-y","article-title":"The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients","volume":"21","author":"Klastersky","year":"2013","journal-title":"Support Care Cancer"},{"issue":"1b","key":"2019111705320853200_B40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1445-5994.2010.02339.x","article-title":"Use of risk stratification to guide ambulatory management of neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee","volume":"41","author":"Worth","year":"2011","journal-title":"Intern Med J"},{"key":"2019111705320853200_B41","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111705320853200_B42","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJM197105132841904","article-title":"Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia","volume":"284","author":"Schimpff","year":"1971","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111705320853200_B43","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1200\/JCO.2012.45.8109","article-title":"Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin\/clavulanic acid combination therapy\u2013EORTC infectious diseases group trial XV","volume":"31","author":"Kern","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1b","key":"2019111705320853200_B44","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1445-5994.2010.02340.x","article-title":"Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee","volume":"41","author":"Tam","year":"2011","journal-title":"Intern Med J"},{"key":"2019111705320853200_B45","unstructured":"National Comprehensive Cancer Network (NCCN)\n          Prevention and Treatment of Cancer-Related Infections V 1.2013\n          Accessed May 5, 2013\n          \n            http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf"},{"issue":"4","key":"2019111705320853200_B46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1473-3099(02)00241-4","article-title":"Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis","volume":"2","author":"Furno","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"7399","key":"2019111705320853200_B47","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bmj.326.7399.1111","article-title":"Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis","volume":"326","author":"Paul","year":"2003","journal-title":"BMJ"},{"issue":"1b","key":"2019111705320853200_B48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1445-5994.2010.02342.x","article-title":"An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009","volume":"41","author":"Lingaratnam","year":"2011","journal-title":"Intern Med J"},{"key":"2019111705320853200_B49","first-page":"CD005197","article-title":"Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams","volume":"11","author":"Paul","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2019111705320853200_B50","unstructured":"Drug safety information for healthcare professionals >information for healthcare professionals: Cefepime (marketed as maxipime)\n          Accessed April 28, 2013\n          available from http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm167254.htm"},{"issue":"35","key":"2019111705320853200_B51","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2012.45.4629","article-title":"Pediatric-Specific Guidelines for Fever and Neutropenia: A Catalyst for Improving Care and Focusing Research","volume":"30","author":"Pulsipher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111705320853200_B52","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/1097-0142(19821201)50:11<2247::AID-CNCR2820501102>3.0.CO;2-7","article-title":"Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia","volume":"50","author":"Stein","year":"1982","journal-title":"Cancer"},{"issue":"1","key":"2019111705320853200_B53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"issue":"6 Pt 1","key":"2019111705320853200_B54","first-page":"668","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients","volume":"86","author":"EORTC International Antimicrobial Therapy Cooperative Group","year":"1989","journal-title":"Am J Med"},{"issue":"10","key":"2019111705320853200_B55","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111705320853200_B56","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111705320853200_B57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/INF.0b013e3181da2171","article-title":"A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia","volume":"29","author":"Maertens","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2019111705320853200_B58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111705320853200_B59","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/510677","article-title":"Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts","volume":"44","author":"Segal","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2019111705320853200_B60","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2019111705320853200_B61","first-page":"e350","article-title":"Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int","volume":"15","author":"Tan","year":"2011","journal-title":"J Infect Dis"},{"issue":"2","key":"2019111705320853200_B62","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/426815","article-title":"A European Organization for Research and Treatment of Cancer\u2013International Antimicrobial Therapy Group study of secondary infections in febrile, neutropenic patients with cancer","volume":"40","author":"Akova","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2019111705320853200_B63","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/clinids\/21.5.1300","article-title":"Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin","volume":"21","author":"Cornelissen","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2019111705320853200_B64","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.22738","article-title":"Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications","volume":"110","author":"Miceli","year":"2007","journal-title":"Cancer"},{"issue":"9","key":"2019111705320853200_B65","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.bmt.1703015","article-title":"Engraftment syndrome following hematopoietic stem cell transplantation","volume":"27","author":"Spitzer","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2019111705320853200_B66","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1093\/annonc\/mdn418","article-title":"Heterogeneity in cancer guidelines: should we eradicate or tolerate?","volume":"19","author":"Pentheroudakis","year":"2008","journal-title":"Ann Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/414\/1251094\/bep00113000414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/414\/1251094\/bep00113000414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T10:32:40Z","timestamp":1573986760000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/414\/20897\/Evidencebased-approach-to-treatment-of-febrile"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.414","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}